by Stephen Manobiano | Oct 7, 2026 | AI, Commercialization, Founders and Business Leaders, Insight, Marketing, Private Equity, Sales, Venture Capital
13 Questions PE Operating Partners Ask About Commercial Value Creation in Life Science Tools, CRO/CDMO, and Diagnostics Portfolio Companies Private equity has become one of the most active sources of capital in life science tools, reagents, CRO/CDMO services, genomics...
by Stephen Manobiano | Aug 25, 2026 | business development, Commercialization, Founders and Business Leaders, Insight, Marketing, Sales
Why referrals and customer mobility, not brand marketing alone, drive new-account growth in life science markets, and how to build the ask into your sales playbook, battle cards, and CRM automation. When I led commercial efforts at GENEWIZ, we made a deliberate bet:...
by Stephen Manobiano | Jul 1, 2026 | business development, Commercialization, CRM best practices, Data Management, Founders and Business Leaders, Fractional, Marketing, news, Sales
NGS isn’t “next gen” anymore. The core sequencing instrument market is dominated by a small number of established platform vendors, and that’s not changing. If your growth strategy still depends on competing for that instrument-level attention, you’re...
by Stephen Manobiano | Jul 1, 2026 | Automation, business development, Commercialization, CRM best practices, Data Management, Founders and Business Leaders, news, Sales
Labs are getting smaller, more automated, and more distributed. Instruments are shrinking and handling more of the manual work themselves. Research hubs outside the traditional life science centers are standing up modular, flexible labs instead of building large...
by Stephen Manobiano | Jul 1, 2026 | business development, Commercialization, Founders and Business Leaders, Fractional, Marketing, news, Sales
Biomarker-guided drug development is now structural, not a passing trend; pharma and biotech companies rely on PD biomarkers to select doses, prove mechanism of action, and stratify patients across oncology, immunology, neurology, and rare disease. If you provide...
by Stephen Manobiano | Jun 30, 2026 | Commercialization, Founders and Business Leaders, Fractional, Marketing, news, Sales
Genome editing is moving from a research tool into therapeutic development pipelines, and that shift is creating real, recurring demand for guide RNAs, delivery reagents, and validation kits. It’s also creating a commercial trap for reagent companies that don’t...
